Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03134196 · ClinicalTrials.gov registry record · Phase 4
Zoster Eye Disease Study
A Phase 4 study of Herpes Zoster Ophthalmicus, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 527
- Enrollment target
- 20
- Study locations
NCT03134196 is a Phase 4 study of Herpes Zoster Ophthalmicus that has completed, run by NYU Langone Health. The registered enrollment target is 527 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT03134196, a Phase 4 study of Herpes Zoster Ophthalmicus, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 527 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment.
Conditions Studied
Interventions
- DRUG Masked Placebo
- DRUG Masked Oral Valacyclovir
Study Locations (20)
California
- Scripps Clinic - La Jolla
- Loma Linda University Eye Institute - Loma Linda
- Jules Stein Eye Clinic - UCLA - Los Angeles
- Byers Eye Institute at Stanford University - Palo Alto
- UCSF- Francis I. Proctor Foundation - San Francisco
- Pacific Eye Surgeons, Inc. - San Luis Obispo
Florida
- Delray Eye Associates, PA - Delray Beach
- University of Florida - Gainesville
- Florida Eye Specialists - Jacksonville
- University of Miami - Bascom Palmer Eye Institute - Miami
Colorado
- University of Colorado - Aurora
- Colorado Cornea Consultants P.C. - Littleton
Illinois
- University of Illinois - Chicago
- NorthShore University Health System - Glenview
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic - Arizona - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2024-07-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03134196
The ClinicalTrials.gov registry entry for NCT03134196 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 527 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Zoster Ophthalmicus appearing as the primary indexed condition, and to 2 interventions - of which Masked Placebo is the first listed.
NCT03134196 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT03134196 about?
NCT03134196 is a clinical study titled "Zoster Eye Disease Study". This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthal...
What is the current status of trial NCT03134196?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 527 participants. The study started on 2017-08-23. Estimated completion is 2024-07-22.
What conditions does trial NCT03134196 study?
This clinical trial studies the following conditions: Herpes Zoster Ophthalmicus.
What interventions are being tested in trial NCT03134196?
The interventions under investigation include: Masked Placebo (DRUG), Masked Oral Valacyclovir (DRUG).
Who is sponsoring clinical trial NCT03134196?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03134196 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.